At the recommended clinical dose for direct application to infected wounds tetrachloro decaoxide (TCDO) (1.0 x concentration TCDO) alone or in combination with haemoglobin proved to be cytotoxic for BHK and Flow 2002 cells, but at :;;;0.1 TCDO/haem concentration BHK-21 cells tolerated treatment with the drug for 24h retaining ;;;:80% cell viability. The in vitro cytotoxic effect is only partially reversible; but this could not explain the strong antiviral effect of TCDO/haem against herpes simplex virus type 1 (HSV-1) growing in BHK cells. The antiviral effect produces both a reduction in the number of virus particles assembled, and a lowering of their relative infectivity (i.e. reduced virus quality). The antiviral effect was active throughout the HSV-1 replication cycle. The quality of the viral DNA that was packaged into particles was unimpaired but unpackaged DNA was less infectious than controls. The reduction in particle numbers appeared to be due to bot~lowered protein synthesis and reduced virus particle assembly. TCDO/haem exhibits potent virucidal activity'against HSV-1; HSV-2; Semliki Forest virus; Germiston virus; Reovirus type 3; Influenza virus type A; Feline leukaemia virus; Adenovirus type 5 and Polio virus type 1. Enveloped viruses, though varying over a wide sensitivity range were more sensitive than non-enveloped viruses. The magnitude of the virucidal effect against HSV-1 in suspension could be reduced by addition of BSA. The HSV-1 virucidal effect stems mainly from an effect of the drug on virion polypeptides. We propose that the effects of TCDO/haem result from the nonspecific chemical oxidation of susceptible chemical linkages both within and between individual proteins located intracellularly (antiviral and cytotoxic effects) or on the surface of virions (virucidal effect).
Summary
At the recommended clinical dose for direct application to infected wounds tetrachloro decaoxide (TCDO) (1.0 x concentration TCDO) alone or in combination with haemoglobin proved to be cytotoxic for BHK and Flow 2002 cells, but at :;;;0.1 TCDO/haem concentration BHK-21 cells tolerated treatment with the drug for 24h retaining ;;;:80% cell viability. The in vitro cytotoxic effect is only partially reversible; but this could not explain the strong antiviral effect of TCDO/haem against herpes simplex virus type 1 (HSV-1) growing in BHK cells. The antiviral effect produces both a reduction in the number of virus particles assembled, and a lowering of their relative infectivity (i.e. reduced virus quality). The antiviral effect was active throughout the HSV-1 replication cycle. The quality of the viral DNA that was packaged into particles was unimpaired but unpackaged DNA was less infectious than controls. The reduction in particle numbers appeared to be due to bot~lowered protein synthesis and reduced virus particle assembly. TCDO/haem exhibits potent virucidal activity'against HSV-1; HSV-2; Semliki Forest virus; Germiston virus; Reovirus type 3; Influenza virus type A; Feline leukaemia virus; Adenovirus type 5 and Polio virus type 1. Enveloped viruses, though varying over a wide sensitivity range were more sensitive than non-enveloped viruses. The magnitude of the virucidal effect against HSV-1 in suspension could be reduced by addition of BSA. The HSV-1 virucidal effect stems mainly from an effect of the drug on virion polypeptides. We propose that the effects of TCDO/haem result from the nonspecific chemical oxidation of susceptible chemical linkages both within and between individual proteins located intracellularly (antiviral and cytotoxic effects) or on the surface of virions (virucidal effect).
Introduction
Anecdotal evidence that tetrachloro decaoxide (TCDO) was of benefit in the treatment of varicella zoster virus 0JZV) lesions in humans (Braun, 1984) encouraged us to investigate whether the preparation has antiviral activity. TCDO is a chloro-oxygen preparation used clinically in Germany for the treatment of wounds infected with diverse pathogens (e.g. Hinz et al., 1984a,b; Sell et al., 1984; Zenker et al., 1986; Kolaric et al., 1988) . Direct application of TCDO has been used in the management of conditions such as impetigo contagiosa, decubital ulcer, chronic leg ulcer, ulcers in wounds, burns, superinfected skin disease and semi-malignant skin tumour (e.g. Von Stahl and Chastany, 1988; Weise and Evers, 1988) .
The chemical structure for TCDO proposed by Ullmann and KOhne (1985) remains controversial. When TCDO is catalysed by haemproteins a reactive oxygen species is liberated, along with CI-and H 20. According to Youngman et al. (1985 Youngman et al. ( , 1986 , the oxidant has a chemical reactivity between that of superoxide and the hydroxyl radical, and shares common characteristics with the Klebenoff system which represents a model for the bactericidal activity of polymorphonuctear leukocytes during phagocytosis (Klebenoff and Rosen, 1979) . TCDO treatment increases the partial pressure of oxygen at the site of treatment (KOhne et al., 1985; Koch, 1985; Weiler-Mithoff et aI., 1989) and stimulates the activity of phagocytic cells (Ullman and KOhne, 1985) . All phases of wound healing are thereby accelerated (Hinz et aI., 1986; Von Foerster, 1987) .
TCDO has two reported effects which are important to anti-microbial chemotherapy. Firstly it stimulates the activity of phagocytic cells, and secondly it kills microorganisms by direct contact -bactericidal activity. It is likely that these effects operate simultaneously in vivo but the sensitivity of different micro-organisms to the direct killing effect of TCDO varies (Gillissen et aI., 1986; Ullman and KOhne, 1985) .
This paper investigates antiviral activity in tissue culture and virucidal activity against HSVand other animal viruses in suspension.
Results
Initial studies showed that the concentration of TCDO died. The additional presence of haem resulted in unimpaired cell viability in cultures treated with TCDO concentrations up to 0.06. There was also 50% survival of cells treated with 0.08 TCDO/haem although these cells did not proliferate subsequently. Thus the cytotoxic effect of 0.08 TCDO/haem was only partially reversed upon removal of the drug. In our subsequent experiments we do not consider that the in vitro cytotoxic effect of TCDO/haem significantly enhanced its antiviral effect: firstly the HSV replication cycle is normally completed within 12 to 16h post infection (p.i.), and secondly the viability of control BHK cultures treated with 0.1 TCDO/haem for 24 h was in almost all experiments ;::'80%. The effect of increasing TCDO/haem concentrations on the 24 h yield of infectious HSV-1 is shown in Fig. 1 . Infectivity in the cell-associated (CA) and cell-released (CR) components of the total yield was reduced by > 10 6 fold in cultures treated with 0.1 and 0.09 TCDO/haem respectively. The viabilities of uninfected cells treated in parallel with TCDO/haem Were virtually unaffected showing that the antiviral and cytotoxic effects were uncoupled. The CR infectivity decreased faster than that remaining CA, suggesting that TCDO/haem inhibits HSV release and/or that the drug has a virucidal effect.
The CA samples from the 24 h dose response curve experiment were examined by electron microscopy (EM), and virus particles, infectivity (as plaque forming units (pfu)), and particle:pfu ratios were estimated (Table 2) . Virus particle numbers decreased with increasing TCDO concentration and at 0.08 TCDO/haem was 180 fold reduced. The particle:pfu ratio increased with drug concentrations >0.04 reaching 107 fold with 0.08 TCDOI haem. Few EM visible virus particles were present in the CR yields, making estimation of particle.pfu ratios impossible. Therefore the antiviral effect ofTCDO, manifested by progressive reduction in HSV particles assembled, with additional loss in their relative infectivity (quality).
To investigate whether the drug inhibits a specific stage in the HSV replication cycle 0.1 TCDO/haem was added at various times after infection, and the 24h CA and CR actually used for the clinical treatment of wounds was cytotoxic for cultured BHK 21 and Flow 2002 cells. As BHK-21 cells (rodent) were more tolerant than the Flow 2002 cells (human) (data not shown) BHK cells were used for the investigation of antiviral activity. The numbers of total cells and viable cells (determined by trypan blue dye exclusion) were estimated in monolayers treated at 37°C for 24 h with increasing concentrations of TCDO alone or TCDO/haem. Two effects were observed: total cell number, and the number of viable cells, were reduced with increasing drug concentration (Table 1) . Haem was protective and reduced the magnitude of both these effects on the cells. Thus 0.04 TCDO alone limited total cell number to 32% of the drug-free control but this rose to 91% when 0.04 TCDO/haem was used. Similarly, 55% of the cells treated with 0.08 TCDO alone remained viable while the viability of cultures treated with up to 0.1 TCDO/haem was not significantly affected.
To check reversibility, monolayer cultures were treated with TCDO or TCDO/haem for 24 h after which the drug was removed, the monolayers washed, overlaid with drug-free medium, and incubation at 3rC continued for a further 3d. Total cell number and their viability was then determined as before (data not shown). While the 3d growth of cells in cultures which had been treated for 24 h with up to 0.04 TCDO alone was subsequently unaffected, cultures which had received higher concentrations of drug infectious yields were determined ( Fig. 2a ). WithouUhe drug the infectious CA yield increased about 3000 fold between 3 and 15 h p.i., but with TCDO/haem no increase was detected. Successively later addition of TCDO/haem resulted in little or no subsequent virus growth ( Fig. 2a ). Thus TCDO operates throughout the viral replication cycle and blocks virus maturation even at a late stage. CA infectivity ceased to increase shortly after drug addition and then slowly decayed suggesting that the virus continued to be released from cells or that a proportion of intracellular infectious virus became progressively inactivated by the drug. The effect of TCDO/haem on CR infectivity is shown in Fig. 2b . Release appears to occur after about 6 h delay following CA virus production. In the absence of drug the CR yield rose about 600 fold between 9 and 24h p.i., while from cultures treated with the drug between 0 and 3 h p.i. no infectious virus is released. Addition at 6h p.i. (when CA progeny Virus had already begun to be produced) and successively later, resulted in ultimately reached levels of CR infectivity which though smaller than the control, approached it. This suggests that TCDO/haem did not prevent the release of already formed infectious virus particles ( Fig. 2b ) and would also explain the progressive decrease in CA infectivity after drug addition ( Fig. 2a ); any intracellular virucidal effect would contribute only to a small measure. As we have evidence (see below) of a virucidal effect of TCDO/haem, the amount of infectious virus actually released is likely to have been greater than that measured.
We measured [3Hj-thymidine incorporated into nascent DNA synthesized in mock-infected (m.i.) or HSV-1 infected TCDO/haem treated cells between 3 and 24h p.i, following banding in CsCI gradients. In rn.l, or HSV infected cells cellular DNA synthesis was virtually unaffected while HSV DNA synthesis progressively decreased reaching 28% of drug-free control with 0.1 TCDO/haem (data not shown). To investigate any effect on DNA quality, the infectivity of viral DNA extracted from cells infected in preserice or absence of TCDO/haem and from HSV particles purified from such cells was determined by transfection assays. Preliminary evidence suggests that the quality of packaged viral DNA is unaffected while that of total infected cell DNA is reduced 12 to 15 fold (data not shown). Thus the high particle:pfu ratio found in the yield of HSV from drug treated cells appears not to be due to change in the infectivity of the packaged DNA; the poorer quality DNA produced in presence of TCDO/haem in HSV infected cells is presumably not packaged. 7.15 X 10 9 6.67 X 10 9 3.33 X 10 9 1.41x10 9 5.72 X 10" 7.15 X 10 7 <10 7 <10 7 pfu mr ' 3.5 X 10" 4 X 10" 3.1 X 10" 2.2 X 10" 7.7 X 10 7 1.7 X 10 7 1.8 X 10 B 2.3 X 10 5 1.8 X 10 4 1.6 X 10 3 7 X 10 '
Particle ptu" Since TCDO/haem does not appear to reduce the quality of packaged viral nucleic acid it must affect some aspects of viral protein synthesis, or induce defects in HSV particle assembly and/or have a virucidal effect.
[ 35S] -methionine labelled infected cell extracts from cultures treated with an increasing concentration of TCDO/haem were analysed by SDS-PAGE. All HSV specified polypeptide bands were slightly reduced in intensity except for the major capsid and the glycoprotein B bands which were markedly reduced by ;;::0.05 TCDO/haem (data not shown).
Incorporation of [ 3 5S]-methionine in presence or absence of TCDO/haem into TCA precipitable material (l.e, protein), was measured in both rn.i, and HSV infected cells to obtain an overall estimate of protein synthesis per se: The effect of TCDO/haem on protein synthesis in m.i. and HSV infected cells was similar. In three separate experiments [ 3 5S]-methionine incorporation into total HSV infected cell proteins in cultures treated with 0.06 and 0.1 TCDO/haem was 54, 32, and 30% and 36, 33, and 24% respectively, of the drug-free level, while the number of HSV particles in cultures treated with the same concentrations of drug are typically 10% and <5% of drug free control. Thus TCDO/haem treatment consistently affected the synthesis of all detectable viral proteins and this correlated with a decrease in the numbers of HSV particles assembled. Virus particle synthesis was affected at least 3 fold more than total protein synthesis. Therefore we propose that the reduction in HSV particle numbers arises from two superimposed effects -a general lowering of protein synthesis in cells, and an effect which operates at the level of virus particle assembly.
To investigate whether the drug has a virucidal effect, HSV-1 or HSV-2 (2 x 10 5 pfu) were suspended in PBS C5 either in the presence or absence of 400 fL9 rnr' haem; various concentrations of TCDO were then added before incubation at 37°C. Samples were withdrawn at various times and assayed. 24 h treatment of HSV-1 at 3JOC (Fig.  3a) with haem alone had little or no effect while treatment with 0.003, 0.01 and 0.03 TCDO alone reduced infectivity by 10, 25, and 25000 fold respectively. With 0.01 TCDO the additional presence of haem increased the 24 h virucidal effect 40 fold. No infectivity survived treatment with 0.03 TCDO/haem for 12 h at 37°C, and already by 6 h, haemoglobin increased the virucidal effect by > 1000 fold. Haemoglobin enhanced the virucidal effect except with very low (0.003) TCDO concentrations (Fig. 3a) . Similar results were obtained with HSV-2 (Fig. 3b) . The presence of haemoglobin increased the virucidal effect of 0.003, and 0.01 TCDO after 12 h incubation by 6 and 16 fold respectively, while no infectious HSV-2 could be detected after only 6h treatment with 0.03 TCDO/haem. Experiments in which HSV-1 and HSV-2 were exposed to higher concentrations of TCDO for shorter periods amply demonstrate the dramatic activating role of haem and the potency of the virucidal effect: whereas little or no effect on HSV-1 infectivity was found after 240 min treatment with haem alone or with 0.1 or 0.2 TCDO alone, only 10 min treatment with 0.1 or 0.2 TCDO/haem resulted in 400 fold and 5000 fold decreases in infectivity respectively (Fig.  3c ). The magnitude of the virucidal effect of TCDO at high concentration on HSV-2 infectivity at 37°C (Fig. 3d ) while very great, was less pronounced: 0.1 or 0.2 TCDO/haem resulted in 500 and 10000 fold reduction in infectivity respectively after 120 min treatment.
The virucidal activity of TCDO/haem was then assessed for the following unrelated but representative DNA and RNA viruses, Semliki Forest virus (SFV; togavirus); Germiston virus (GV; bunyavirus); Reovirus type 3 (Reo-3, reovirus); Influenza virus type A (Flu A, orthomyxovirus); Feline Leukaemia virus (FLV, retrovirus); Adenovirus type 5 (Ad-5, adenovirus); Poliovirus type 1 (PoIi0-1, picornavirus).
The results with SFV are shown in Fig. 4a . While infectivity of the drug-free control fell about 6 fold after 24 h incubation at 37°C, 5h treatment with 0.05 and 0.1 TCDO/haem, resulted in a 30000 and 250000 fold loss respectively. Germiston virus was stable during the 24h incubation at 37°C in the absence of TCDO/haem, but infectiVity dropped >10000 fold and >1000000 fold within 1 h when treated with 0.05 and 0.1 TCDO/haem respectively (Fig. 4b) . Ad-5 infectivity fell 130 fold in 24 hat 3rC in the absence of drug. The presence of 0.05 and 0.1 TCDO/haem in the suspension further reduced infectivity by 15 and 300 fold respectively (Fig. 4c ). Polio-1 infectivity was reduced 2 fold by 24 h incubation at 37°C in the absence of drug, while the presence of 0.05 and 0.1 TCDO/haem only resulted in a further 3 fold or 6 fold decrease respectively (Fig. 4d) . Therefore, Polio-1 was resistant to these concentrations of TCDO/haem. Reo-3 was unaffected by 24 h incubation without drug at 37°C, while 1 h treatment with 0.05 TCDO/haem resulted in a 160 fold reduction progressing by 24 h to a 7000 fold drop of initial infectivity (Fig. 4e ). Flu A infectivity fell about 10 fold within 24 h of incubation at 37°C. Three hours of treatment with 0.05 and 0.1 TCDO/haem resulted in losses in infectivity of 1000 fold and> 10000 fold respectively (Fig.  4f) . The virucidal activity of TCDO/haem for FLV is shown in Fig. 4g . FLV infectivity was stable at 3JOC for 6h in absence of drug, while 0.01, 0.025, and 0.05 TCDO/haem resulted within 3 h respectively in a 10 fold and a 1000 fold and >500000 fold loss in infectivity. These results demon-strate that the TCDO/haem sensitivity of different viruses in suspension varies widely. The effect of increasing protein concentration on the virucidal activity of TCDO/haem was examined by adding bovine serum albumin (BSA) to HSV-1/drug mixtures. infectivity after 60 min. The additional presence of 5 mg mr' or 10 mg mr' BSA protected and greatly diminished the virucidal effect to only 10 fold and 3 fold respectively (data not shown). Thus addition of BSA to the virus/drug suspension (itself in 5% calf serum) modulates the virucidal effect ofTCDO/haem. Differences in the overall protein concentration of individual stocks of virus, arising from varying amounts of cellular debris, serum, and virus particle:pfu ratios, can therefore be expected to influence the experimental results. Hence the amounts of protein associated with each virus stock used for Figs 3 and 4 have been estimated by Pierce BCA protein assay ( Table  3) .
Relative to PBS C5 and haem they ranged from 100 to 167% although most fell between 110 and 120% and thus they cannot account for the observed great differences in TCDO/haem sensitivity of the different viruses.
The virucidal effect of TCDO/haem against HSV must operate either by interacting with the packaged nucleic acid, or with virion structural polypeptides, or both. Hence, the infectivity of DNA extracted from particles inactivated following treatment with 0.2 TCDO/haem was examined. 10810g 10 pfu of HSV-1 (strain F)was suspended in PBS C5 containing either haem alone or 0.05 or 0.1 TCDO/haem and incubated at 37°Cfor 24 h. Aliquots were withdrawn at Oh and 24h and assayed for infectivity. DNA was extracted from the control and drug treated virions after 24 h incubation and the infectivity of the DNA checked by transfection. Treatment of HSV-1 virions with 0.05 and 0.1 TCDO/ haern at 37°C for 24h reduced virus infectivity by 6x10 4 and 1x 10 6 fold respectively while the infectivity of the virus in the drug-free sample during this period had decreased only 3 fold. When the infectivity of the DNAs extracted from virions inactivated by treatment with 0.05 and 0.1 TCDO/haem is compared with the infectivity of the DNA extracted from drug-free virus suspensions there was only a minor reduction in DNA infectivity to 31% and 12% of control level for 0.05 and 0.1 TCDO/haem respectively, which cannot account for the much greater loss in virus particle infectivity. The results demonstrate that virtually the whole virucidal effect of TCDO/haem against HSV operates by affecting the structural proteins and envelope of the virion or their interrelationships.
Discussion
We have demonstrated that TCDO/haem has antiviral and virucidal activities. These two effects are independent: antiviral activity could block the virus replication cycle at any stage to final virus assembly and maturation and results from drug-induced effects on one or more virus specified, or cell specified functions essential for virus growth; and virucidal effect is the result of inactivation of infectious mature virions following direct contact with the drug.
The clinical dose of the drug which is normally used (1.0 TCDO) proved to be cytotoxic to cells in tissue culture. This was unexpected in the light of extensively documented clinical experience where TCDO is applied on a moistened compress to raw tissue (i.e. amputation stumps) at least twice daily for up to six weeks, promoting good healing without apparent serious cytotoxic effect. In our in vitro experiments, the viability of BHK cells treated with 0.1 TCDO/haem for 24 h at 37°C was usually ;:,:80% (Table 1; Figs 1 and 2) ; the amount of [3Hl-thymidine incorporated into cellular DNA was about 80% of the control level; while the amount of [ 35S1methionine incorporated into cellular protein over the 24 h period was between 25% and 40% of the control level (data not shown). Thus TCDO/haem at 0.1 concentration does not have a strong cytotoxic effect on BHK cell cultures incubated at 37°C for 24h, and We conclude that the majority of the cells are live and retain metabolic activity. However, BHK cultures treated with 0.08 and 0.1 TCDO/ haem for 24 h did not proliferate during the 3-d period following removal of the drug which suggests that it is not easily removed from treated cells and/or that the in vitro cytotoxicity is progressive and probably becomes irreversible. Nevertheless, because the HSV replication cycle is generally completed within 12-16h p.i. (Fig. 2) we can exclude cell death as the explanation for the pronounced antiviral effect of TCDO/haem in our experiments.
The potent antiviral activity of TCDO/haem on HSV-1 does not operate by inhibiting the function of any single essential virus gene product but has a more general rnode of action. The antiviral effect manifests as a reduction in the numbers of virus particles assembled exacerbated by their diminished relative infectivity. Reduction in HSV particle yield stems from two effects: a general one on protein synthesis in drug treated cells, and another which operates at the level of virus particle assembly. The reduced progeny virus infectfvity is not due to an effect of TCDO/haem on packaged viral DNA (although un-packaged DNA has reduced infectivity) but results from the virucidal affect of the drug and/or imperfect assemblyl maturation of the virus particles leading to lower relative quality. Comparison of the CA and CR infectious yields in constant presence of the drug shows that the virucidal effect can not provide the full explanation ( Fig. 2a and b) . While there is some loss, much of the cell associated infectious virus is subsequently released into the medium.
The virucidal spectrum of TCDO/haem was examined using viruses representing several different virus families and these ranged from extreme sensitivity to virtual total resistance. In general the enveloped viruses were much more sensitive than the non-enveloped polio and adenovirus (Table 3) . Although the concentration of total protein can modulate the magnitude of the virucidal effect this cannot account for the huge differences in TCDO/haem sensitivity we observed for different viruses, which points to intrinsic differences distinguishing the virus families.
The molecular mechanism by which TCDO/haem imparts a virucidal effect has not been studied by us but almost certainly involves the oxidant liberated when TCDO is catalysed by haemoglobin (Youngman et a/., 1985 (Youngman et a/., , 1986 .The mechanism is not necessarily analogous to that of the reported bactericidal effect of the drug (Ullman and Kiihne, 1985) .
Electron microscope studies of HSV particles inactivated by TCDO/haem treatment (data not shown) failed to detect any morphological differences between preparations of inactivated virus and infectious control virus indicating that the chemical action of TCDO/haem does not result in the de-envelopment or disruption of the virus particle. We propose therefore, that the virucidal effect of TCDO/haem derives from oxidation of susceptible chemical bonds within individual proteins and/or which occur between different proteins, either on the surface or in the tegument or core of the virion, thus recfucing the probability of successful initiation of the infective process.
Materials and Experimental procedures
Cells BHK and Hela cells were grown in Eagle's medium supplemented with 10% calf serum (EC10) and 5% foetal calf serum (EFC5) respectively. BSC-1 and MDCK cells were grown in Dulbecco's minimal essential medium containing 10% foetal Calf serum (DFC10)while QN10 cells were grown in DFC10 containing 25 mM hepes buffer, 1% non-essential amino acids and 10% tryptose phosphate broth (DhFc1 0). For protein labelling of uninfected and HSV infected BHK cells the serum concentration was reduced to 5%.
Viruses
The viruses used were herpes simplex virus types 1 and 2 (HSV-1, Antiviral and virucidal activities of TCDO 103 strain 17 syn": HSV-2, strain HG52), Semliki Forest virus (SFV), Germiston virus (GV), Influenza virus type A (Flu A), Feline leukaemia virus type A (FLV), Reovirus type 3 (Reo-3), Poliovirus type 1 (Polio-1), and Adenovirus type 5 (Ad-5).
Virus plaque assays
Ten-fold serial dilutions of virus were prepared in phosphate buffered saline containing 5% calf serum (PBS C5) (except for Flu A which was diluted in PBS only). HSV-1, HSV-2, SFV, and GV; plaque assays were performed using BHK cell monolayers, Reo-3 and Polio-1 were assayed on BSC-1 monolayers, while MDCK, QN10 and Hela cells were employed for Flu A, FLV, and Ad-5 assays respectively. With the exception of FLV the medium was removed from monolayers before infection. Virus absorption to cells was for 1h (2-4h for FLV) at 37"C (31°C for GV; 34°C for Polio-1). 4fL9 mr" polybrene was present during the FLV absorption period. The cell layers were then washed three times with PBS C5 (PBS alone for Flu A; DhFC10 for FLV) and the infected cells then overlaid with EC10 containing 3% carboxy methyl cellulose (HSV-1, HSV-2), DhFC10 (FLV), EC3 containing 0.6% agarose (SFV, Reo-3, PoIi0-1, and GV), EC3 containing 0.6% Noble agar (Ad-5), or Eagles medium lacking serum but containing 4 fLg mr' trypsin (Flu A).
Plaque assays were maintained at the absorption temperature but the incubation period varied: 2 d for HSV-1, HSV-2, Po1i0-1 and Flu A; 5d for GV and Reo-3; and 7-10d for Ad-5 and FLV. Ad"5 infected cell layers were augmented after 3 d incubation while the medium was replaced on FLV infected cell cultures after 2d incubation and again after 5d. After cpe developed the infected cell layers were fixed, stained and the numbers of virus plaques counted.
Drugs
The commercially available WF10 TCDO solution (100ml) contains TCDO prepared in 2% glycerol. Because the chemical formula of TeDO has not been generally accepted molar concentrations could not be used, furthermore the manufacturers supply no information regarding the concentration of TCDO in terms of mg rnr', We are, therefore, forced to calibrate concentrations relative to that recommended for the clinical treatment of wounds.
To obtain the clinical dose (I.e. 1.0 x concentrated TCDO) the commercial stock solution withdrawn by syringe was diluted 1:4 with sterile distilled water. The never opened commercial stock solution was stored in the dark at 4°C and fresh dilutions were prepared from syringe withdrawn aliquots for each experiment.
We have used sterile bovine haemoglobin (haem) at 400 fL9 mr' to catalyse TCDO. The drug was never pre-mixed with haem but was always the final component to be added to infected cell cultures or virus suspensions.
Estimation of total cell number and percentage cell viability
BHK cells were seeded at 1 x 10 6 cells 30mm-1 dish and incubated at 37"C for 18 h; monolayers were then treated with various concentrations of TCDO alone or TCDO/haem at 37"C for 24h. Cultures were then harvested as described in Dargan and Subak-Sharpe (1985) and cell viability estimated by trypan blue dye exclusion.
HSV-1; TODD/haem dose response curve BHK cells were infected with HSV-1 at 5 pfu cell-l . After 1 h absorption at 37"C the cells were washed three times with PBS C5 then overlaid with 2 ml EC10 containing 400 J.l.g ml-l haemoglobin, TCDO was then added to various concentrations. After 24 h incubation at 37" the growth medium was removed and cell debris pelleted by low speed centrifugation. This clarified supernatant was the cell released (CR)virus preparation. The pellet was pooled with the cell monolayer which was scraped into 2ml of EC10 and the cell associated (CA) virus released by ultrasonic treatment. The infectious virus yield was determined by plaque assay. The viabilities of unirifected cells, treated in parallel with TCDO/haem were also determined.
Virus particle counts were estimated using a Siemens 101 electron microscope and phosphotungstic acid stained preparations as described by Wildy et al. (1960) .
Addition of TODD/haem during the HSV-1 replication cycle
BHK monolayers were infected with 5 pfu HSV-1 cell"". After the absorption and washing procedures the infected cells were overlaid with EC10 containing 400 J.l.g mr' haemoglobin. TCDO, to 0.1 concentration, was added to sets of infected cells at various times p,i. At the indicated times, selected cultures were harvested and the virus yield separated into CA and CR components. Samples were stored at -70°C until all the samples could be titrated together.
The viability of m.i, cells treated throughout with 0.1 TCDO/ haem were determined at various times during the experiment.
Quantitation of DNAs from m.i. and HSV-1 infected BHK cells treated with TODD/haem
Cells were either m.i. or infected with HSV-1 at 5 pfu cell-l . After the absorption and washing procedures the cells were overlaid with EC10 containing 400 Jig rnr:" haemoglobin. TCDO was then added to 0.02, 0.04, 0.06, 0.08, and 1.0 and incubation at 37"C continued until24h p.i, Nascent DNA was labelled from 3 to 24h p.i. with 50J.l.Ci rnr" [3H]-thymidine (18-25 mCi mmor ') after which cells were harvested and pelleted by low speed centrifugation. Extraction of DNAs, CaCI gradient centrifugation conditions and quantitation of DNAs were all as described in Dargan and Subak-Sharpe (1986) .
Transfection infectivity of the total and packaged HSV-1 DNAs from infected cells treated with TODD/haem
BHK cells were infected at 10 pfu HSV-1 cell~l. After the absorption and washing procedures the monolayers were over-" laid with EC10 containing 400 J.l.g ml-l haemoglobin, and TCDO then aded to final concentrations of 0.06 and 0.1. After 24 h incubation at 37"C total infected cell DNA and DNase 1 resistant packaged HSV DNA was extracted from parallel cultures (Stow et al., 1983) . The DNAs were then used in transfection.assays (Stow et al., 1976) : Transfection of total infected cell DNA was performed in triplicate while transfection of packaged HSV-1 DNAs was performed in duplicate. The plaques arising from transfections were counted and averaged. The number of EM visible HSV particles in each packaged DNA sample was determined priorto DNA extraction.
SDS-PAGE
BHK cells were either m.i, or infected with HSV-1 at 20 pfu ceir'.
After the absorption and washing procedures the cells were overlaid with Eagles medium, having ol'lly 20 0 /0 of the normal concentration of methionine, and containing 5% calf serum and 400J.l.g mr' haemoglobin. TCDO was then added to 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, and 0.1 and incubation continued at 37"C. At 3h p.l, 10J.l.Ci ml-1 [35S]-methionine was added and incubation resumed until 24h p.i, The preparation of infected cell extracts and SDS-PAGE conditions were as described by Marsden et al. (1976) .
Determination of virucidal activity
Virus was prepared in PBS C5 + 400 J.l.g rnl" haemoglobin to give between 10 5 and 10 8 pfu rnr ' depending upon the virus stock available. TCDO was added to various concentrations and the virus/drug mixtures incubated at 37"C for up to 24h. At various times after drug addition 250 J.l .1 aliquots of virus/drug mixture were withdrawn and surviving infectivity determined by titration and plaque assay.
